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Abstract
Background: Chronic Obstructive Pulmonary Disease (COPD) is a multi-systemic and progressive disease. However the
determinants of its impact on health related quality of life are not well-studied or understood in Nigeria.
Objectives: To assess the determinants of  health related quality of  life in COPD
Methods: Patients with stable COPD were recruited consecutively from the outpatient clinics of a university hospital.
Health Related Quality of  Life (HRQL) was assessed using the St. George’s Respiratory Questionnaire (SGRQ) and the
Forced Expiratory Volume in one second (FEV1), Forced Vital Capacity (FVC) were measured by a vitalograph spirometer.
Results: Fifty patients were recruited for this study (male= 60%). The mean (SD) age was 69 (9) years. The overall mean (SD)
SGRQ scores was 45.9 (26.5), 50.6 (29.2), 29.7 (19.9), 38.8 (22.0) for the symptom, activity, impact and total scores respectively.
After adjusting for age, sex and smoking, self-reported breathlessness independently predicted on average 25.2, 36.8, 13.65
and 22.9 points increase in SGRQ symptom, activity, impact and total scores respectively. Self-reported weight loss predicted
12.2 points increase in the impact subscale.
Conclusions: Self-reported breathlessness and weight loss are independent predictors of  low HRQL score in COPD.
Key words: Chronic obstructive pulmonary disease, Health related quality of  life, St George’s Respiratory Questionnaire,
Nigeria.









Chronic Obstructive Pulmonary Disease (COPD)
is a growing cause of  morbidity and mortality. It is
projected to become the third leading cause of death
worldwide by 20301, 2. Although significant progress
has been made in the assessment and management
of patients with COPD over the last four decades,
the care of persons with this disease remains
challenging because of  it’s progressive and multi-
systemic nature.
COPD is usually assessed using outcome
measures like number of hospitalization,
exacerbations, mortality and lung function parameters
3, 4. However these measures do not provide a
comprehensive assessment of the health status of
the patients. There is growing evidence that shows
that relying only on mortality and lung function
measures for assessing effectiveness of treatments
could be misleading in conditions like COPD that
have notable non-respiratory systemic
manifestations5, 6. As such, Health Related Quality of
Life (HRQL) measures have achieve widespread
acceptance because they provide a holistic assessment
of the impact of the disease and benefits of
treatments. Among these quality of  life measures,
the St Georges Respiratory Questionnaire (SGRQ)
has been shown to be valid and specific for COPD7,
8.
Quality of life (QoL) evaluation is relatively new in
developing countries. It can influenced by various
factors including socio-economic status and may
vary between populations9, 10. We are unaware of
any study in Nigeria that has assessed the quality of
life of  patients with COPD.  The relation of  QoL
measures to traditional outcomes of COPD like lung
function measures and the factors that predict them
are not well understood.
The use of quality of life instruments holds potential
use in rural and suburban health facilities in
developing countries where access to spirometry and
other objective measures of lung function may be
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lacking. The availability of  adapted QoL measures
may provide substantial and complementary benefit
for patients with COPD and their care providers.
The aim of this study was to assess the relation of
SGRQ scores to lung function especially forced
expiratory volume in one second (FEV1), forced
vital capacity (FVC) and to determine the factors
that predict its component and total scores.
Methods
Study design
It was a cross-sectional study carried out at the
medical outpatient department of Obafemi
Awolowo University Teaching Hospital (OAUTH),
Ile-Ife. OAUTH is a tertiary hospital located in
southwest Nigeria.
Study participants
Fifty (50) patients with stable COPD according to
the Global Initiative for Chronic Obstructive Lung
Disease (GOLD) criteria were recruited consecutively
from the outpatient clinics of  Obafemi Awolowo
University Teaching Hospital (OAUTH), Ile-Ife11.
The inclusion criteria comprised of patients with:
1. chronic airflow impairment – percentage of
forced expiratory volume in one second less than
80% predicted and ratio of forced expiratory volume




2. a bronchodilator reversibility test with change in
FEV
1
 less than 15% and/or 200ml 20minutes after
inhalation of 400micrograms of Salbutamol,
3. clinically stable as defined by no change in
medication dosage, frequency and no exacerbation
or hospital admissions in the preceding six weeks.
Those excluded were; persons with a history of
asthma, atopy or nasal polyps, patients who
demonstrated a remarkable response and reversibility
to Salbutamol as noted by FEV1 change above 15%
and/or 200ml, patients with active lung disease like
Tuberculosis or Bronchiectasis and those with co-
morbid conditions that could contribute to dyspnoea
or exercise limitation like hypertensive heart failure
Measurements
Health Status Measurement
HRQL was assessed using the SGRQ8. The SGRQ
has been used extensively for assessing QoL in patients
with COPD and several other chronic lung diseases12-
14. It was developed by PW Jones of  the St George’s
hospital medical school, London in 1991. It is
sensitive, valid, reliable and responsive among
patients with COPD. It contains 50 items with 76
weighted responses that cover three domains:
symptoms – distress due to respiratory symptoms,
activity – disturbances of physical activity and impact
– overall impact on daily life and well-being.  In
addition to the domain scores, there is also a total
score7. The SGRQ is scaled from zero to 100 (with
zero representing the best health-related quality of
life). This questionnaire which was forward and back
translated in Yoruba language, was administered to
each participant.  However those unable to self-
complete the questionnaire due to shaky hands,
inability to read, or poor eye sight had the
questionnaire read to them in the exact format in
which they were set out without bias or undue
emphasis and their responses were ticked as
appropriate.
Lung function parameters
Lung function test was performed using a
standardized vitalograph bellows spirometer
(Vitalograph Ltd, Buckingham, England). The
following parameters were measured: forced
expiratory volume in one second (FEV-
1
) and forced
vital capacity (FVC).  The reference values
were derived using equations from a study by Femi-
Pearse et al15. The parameters were assessed before
and 20 minutes after the inhalation of 400ìg of
Salbutamol using a metered dose inhaler (MDI) and
a spacer device.  The spacer was attached to the
MDI and held in the mouth.  After the patient had
exhaled to functional residual capacity (FRC), the
canister was activated.  The patient inhaled slowly to
total lung capacity (TLC) and held his/her breathe
for ten (10) seconds16. This was done twice for every
200µg of Salbutamol released into the spacer device.
Exercise testing and dyspnoea rating
Exercise performance was evaluated using the six
minutes walk test (6-MWT) according to the
American Thoracic Society guideline17. It is a simple,
easy to administer and well tolerated functional
walking test which is representative of the   activities
of  daily living (ADL). This test was performed on a
long, flat, straight and enclosed corridor.  The walking
course was 30m (100 –feet).  The length of the
corridor was marked every 3m and the turnaround
points were also noted.  A starting line, which marks
the beginning and end of  60m lap, was marked on
the floor using a brightly coloured marker. Patients
appeared in their normal clothing on the day of  the
test with their shoes and walking aid, if  any.  The
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length walked was measured and the level of
perceived breathlessness was measured both before
and after the walk test using the visual analogue scale
(VAS)
The VAS is a dynamic scale used to assess a patient’s
perceived breathlessness. It has been shown to be a
valid measure of dyspnoea on exertion18. The visual
analogue scale consisted of a 20cm horizontal line.
The word ‘No Breathlessness’ was written at the left
end of  the scale, ‘Very Severe Breathlessness’ was at
the right end of the scale. It was scored from 0 to
100. Ratings were expressed as percents of the full
VAS line length. Participants were asked to grade
their shortness of breath with the scale before and
after the six minutes walk test.
Data collection and Analysis
A proforma was used in recording socio-
demographic data from each patient. Mean values
and standard deviation (SD) was computed for all
continuous parameters and frequencies and
proportions for categorical variables. The correlation
between quality of life scores, dyspnoea rating, six
minutes walking distance and physiological
parameters was assessed using Pearson’s linear
correlation coefficient.
The St Georges respiratory questionnaire
was statistically analyzed using the excel-based scoring
calculator from the developer. To identify the factors
that influenced HRQL in these patients, a linear
regression analysis was used. The model with the
best fit was assessed using the changes in the R-
squared values adjusting for age, sex and smoking
pack years. Ethical clearance was obtained from the
hospital ethics committee and verbal informed
consents were obtained from participants included
in the study.
Results
Fifty patients were recruited for this study and sixty
percent of the respondents were male. The mean
age and standard deviation was 69 (9) years, body
mass index (BMI) 22(5). The proportion of the stages
of COPD were 10%, 34%, 34% and 22% for mild,
moderate, severe and very severe stages of the
disease respectively. The mean pre-bronchodilator
FEV1 and FVC were 801ml and 1520ml while the
post bronchodilator FEV1 and FVC were 817ml
and 1570ml respectively. The overall mean (SD)
SGRQ scores were 45.9 ± 26.5, 50.6 ± 29.2, 29.7 ±
19.9, 38.8 ± 22.0 for the symptom, activity, impact
and total scales respectively (table 1).
Table 1: General characteristics of  the
participants (n=50)
Variable                        Mean ± SD or n (%)
Age (years) 69 ± 9
Height (cm) 162 ± 9
BMI (Kg/m2) 22 ± 5
FEV1-pre (ml) 801 ± 439
FEV1-post (ml) 818 ± 405
FVC-pre (ml) 1520 ± 679
FVC-post (ml) 1570 ± 655
FEV1/FVC (%) 51 ± 12
6 MWD (m) 361 ± 85
VAS-dyspnea before 6MWD(%) 10 ± 15
VAS-dyspnea after 6MWD (%) 29 ± 22
SGRQ score
 Symptom 45.9 ± 26.5
 Activity 50.6 ± 29.2
Impact 29.7 ± 19.9
Total 38.8 ± 22.0
Sex (male) 30 (60)











FEV1 – Forced expiratory volume in one second,
FVC- Forced vital capacity, pre- prebronchodilator,
post-bronchodilator, VAS- visual analogue scale,
SGRQ- St George’s Respiratory Questionnaire,
BMI- Body Mass Index; 6 MWD-6 Minutes Walking
Distance. GOLD- Global initiative for Chronic
Obstructive Lung Disease;
*Post bronchodilator FEV1/FVC <70%. FEV1 >
80% predicted (Mild); 50% <= FEV1 < 80%
predicted (Moderate); 30% <=FEV1 < 50%
predicted (Severe); FEV1 < 30% predicted (Very
severe).
Men had mean (SD) SGRQ scores of 42.1 (27.8),
47.5 (30.8), 27.2 (20.3), 36.0 (22.9) and for women
the scores were 51.6 (23.9), 55.2 (26.7), 33.4 (19.2),
43.0 (20.4) in the symptom, activity, impact and total
scales respectively. Women had worse SGRQ scores
compared with men. As expected, previous heavy
smokers had worse SGRQ score in the symptom
subscale compared to never smokers (Data not
shown). There was no current smoker in the sample.
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Table 2 shows the correlation coefficients
between the SGRQ scores, lung function parameters,
six minutes walking distance and VAS dyspnoea
scores. The coefficients for FEV1 pre-bronchodilator
were -0.19, -0.36, -0.26 and -0.31 for SGRQ
symptoms, activity, impact and total scores
respectively. The coefficients for pre- bronchodilator
FVC were -0.13, -0.32, -0.18 and -0.24 respectively.
The coefficients for pre-bronchodilator FEV1 and
FVC were higher than the post bronchodilator values.
The VAS scores post exercise showed correlation
coefficients of 0.16, 0.36, 0.41 and 0.38 for SGRQ
symptoms, activity, impact and total scores
respectively. The activity subscale and total score
demonstrated the best SGRQ correlation to FEV1,
albeit weak, to lung function variables.
Table 3 shows the results of  the univariate
analysis of  the various study parameters. Notably,
Table 2: Pearson correlation coefficient of  SGRQ scores
the self reported dyspnoea and weight loss were
important predictors for the SGRQ total and sub
scores. Those reporting dyspnoea on average had
27.82, 29.46, 10.70 and 19.48 points higher scores
(indicating worse quality of life) in the total,
symptoms, activity and impact scales respectively.
Table 4 presents the result of  the
multivariate analysis adjusting for age, sex, smoking
and FEV1.  It shows that self reported breathlessness
independently predicts on average 25.2, 36.8, 13.65
and 22.9 points increase in SGRQ symptom, activity,
impact and total scores respectively. Adjusting for
age, sex, pack years of smoking, reported symptoms
like weight loss, breathlessness, VAS score post
exercise and lung function, the model accounted for
24%, 42%, 27% and 35% of the variance in the
SGRQ symptom, activity, impact and total score
respectively.
Symptom Activity Impact Total
FEV1- Pre -0.19 -0.36* -0.26 -0.31*
FEV1-Post -0.13 -0.32* -0.21 -0.26
FVC-Pre -0.13 -0.32* -0.18 -0.24
FVC-Post -0.07 -0.24 -0.14 -0.18
FEV1/FVC -0.07 -0.25 -0.14 -0.18
6 MWD -0.21 -0.24  -0.32*  -0.30*
VAS -Post 0.16  0.36*   0.41**   0.38**
exercise
* p <0.05   ** p<0.01
FEV1 – Forced expiratory volume in one second, FVC- Forced vital capacity, PRE- prebronchodilator,
POST-bronchodilator, VAS- visual analogue scale, SGRQ- St George’s Respiratory Questionnaire, 6 MWD -
6 Minutes Walking Distance, Significant values in bold
Discussion
The SGRQ designed by Jones PW has been used
widely for measuring HRQL in persons with COPD
especially in drug trials and other controlled
interventional studies19, 20. Recently, a shorter version
derived from the SGRQ, which is described as
COPD Assessment Test (CAT) was developed by
the same author21. However the use and relevance
of these assessment tools in patients in low-income
countries where access to respiratory care, spirometry
and other modalities of managing COPD are largely
inaccessible, is not well studied or understood.
We found that patients with COPD had low self-
perceived quality of life especially in the ‘symptom’
and ‘activity’ subscales of  the SGRQ. HRQL showed
a significant association with dyspnoea measures but
showed weak and inverse relationship with
spirometry. In addition, self  reported dyspnoea and
weight loss were the strongest independent
predictors of HRQL.
The quality of life scores of the present study
generally indicate the patients had poor health status.
In healthy individuals without symptoms of
respiratory diseases, SGRQ scores are usually less
than 15 units 22and in clinical trials on patients with
COPD, the minimum clinically important difference
(MCID) for efficacy of a treatment is estimated to
be 4 units23, 24. However, in cross sectional studies of
diseased individuals, a relative approach is often
used.in interpretation of  SGRQ scores. Scores
tending towards 100 are generally indicative of worse
health status while scores tending towards 0 indicate
a better quality of life score7.
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Table 3: Univariate regression analysis of  SGRQ total and component scores on study parameters
Total Symp- Activity Impact
tom
Age (years)  0.16 -0.12  0.33  0.18
Sex (Male) -6.99 -9.47 -7.70 -6.16
Height (cm)  0.03 -0.24 -0.06  0.15
BMI (Kg/m2) -0.14  0.32 -0.06 -0.32
Smoking status -1.32 -1.13 -0.52 -1.86
Smoking pack years  0.07 0.44 -0.23  0.08
6 MWD (m) -0.08 -0.07 -0.08 -0.08
FEV1-pre -0.02 -0.01 -0.02 -0.01
FEV1-post -0.01 -0.01 -0.02 -0.01
FVC-pre -0.01 -0.01 -0.01 -0.01
FVC-post -0.01  0.00 -0.01 0.00
FEV1/FVC -0.35 -0.16 -0.63 -0.24
VAS 1  0.31 0.38 0.30 0.28
VAS 2  0.38 0.19 0.48 0.37
Gold classication  2.69 0.70 5.27 1.56
Self-reported symptoms
Cough -7.16 4.10 -36.03 5.65
Sputum 16.87 23.42 17.11 14.60
Wheeze  6.54 12.92 6.72 4.23
Dyspnea 27.82 29.31 40.93 19.48
Weight loss 16.38 15.86 17.26 15.53
Chest tightness 6.43 13.46 10.70 1.51
Chest pain 5.61 6.59 7.14 4.92
Occupation 0.34 0.75 1.01 -0.07
Cooking fuel* -1.84 -6.48 -1.94 -0.61
GOLD - Global initiative for chronic Obstructive Lung Disease. VAS1 – Visual Analogue Score pre-exercise,
VAS 2 – Visual Analogue Score post-exercise, BMI= Body Mass Index; FEV1 – Forced Expiratory Volume
in one second, FVC- Forced Vital Capacity, pre- prebronchodilator, post-postbronchodilator, SGRQ- St
George’s Respiratory Questionnaire, BMI- Body Mass Index, 6 MWD -6 Minutes Walking Distance.
*Cooking fuel types included Firewood, Kerosene, Liquefied natural gas and Electric cooker
Significant variables at p<0.05, are in bold
We found weak correlation between HRQL and
Spirometry. The activity and total scales of  the SGRQ
showed the best correlation with pre-bronchodilator
FEV1, but the coefficients were generally low (Figure
1a-d). A similar observation was found between
SGRQ total score and post bronchodilator lung
function values (Figure 2). Various correlation
coefficients have been reported between HRQL and
spirometry by several authors but the coefficients
are usually weak 8, 25. Spirometry objectively evaluates
the lung’s functional and ventilatory capacity however
it often fails to evaluate the non-ventilatory
manifestations of COPD like weight loss, mood
changes including depression. Overall, it seems that
spirometry and HRQL are important tools, which
evaluate different aspects of the disease especially
the impact on patients daily functioning. Spirometry
evaluates the functional aspects of the airway calibre
and informs on the progression of  the disease, a
measure described as a ‘hard’ measure by PW
Jones26. However HRQL provides a holistic
evaluation of the total impact of the disease especially
in manifestations other than airway obstruction like
weight loss, mood swings which explains its
description as a ‘soft’ measure26. The combination
of quality of life measures to the functional measures
obtained from spirometry may provide a more
thorough and comprehensive evaluation of patients
with COPD.
The notable predictors of HRQL were self-
reported breathlessness, weight loss, wheeze, sputum
production and patient’s subjective perception of
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Table 4: Multivariate regression analyses of  determinants of  health related quality of  life
CI- Confidence Interval; FEV1- Forced Expiratory Volume in one second; VAS- Visual Analogue Scale;
SGRQ - St George’s Respiratory Questionnaire; SE- Standard Error; Post - postbronchodilator
The model adjusted for age, sex and smoking with SGRQ ‘total’ ‘symptom’ ‘activity’ and ‘Impact’ scores as
dependent variables               Significant variables at p<0.05, are in bold
breathlessness measured on the visual analogue scale
post exercise. Age, body mass index, social class and
GOLD staging of the disease did not significantly
influence or predict HRQL. However, in the
multivariate model, the key predictor of HRQL was
self  reported breathlessness. This observation shows
that breathlessness during exercise or performance
of  daily activity is an important determinant of
patient’s self-perceived quality of  life. Our study
corroborates previous studies which showed that
dyspnoea is one of  the main determinants of  the
disease-specific HRQL and has moderate-to-strong
correlation with impairment in the HRQL of
patients with COPD27, 28.
In the symptom subscale, dyspnoea was the
only significant explanatory variable independently
accounting for 27% of the variance in the quality of
life sub score. The classical symptoms of COPD
like cough, sputum production and wheeze were
not found to influence significantly on quality of life
neither did functional variables like FEV1. This
observation shows that breathlessness occupies an
overriding influence on HRQL over other symptoms
of the disease. In the activity subscale, breathlessness
accounted for a greater proportion of the variance
in the HRQL, representing 42% of the total variance
in this subscale. This further shows that restriction in
activity in COPD is primarily due to breathlessness.
The variance in the impact subscale was also
influenced independently by the perception of
breathlessness, weight loss and dyspnoea score on
the VAS post exercise. They accounted for 24% of
the total variance in this subscale. The relatively low
percentage in the accounted variance of the impact
subscale model may be due to the fact that anxiety
and depression were not measured in this study.
Anxiety and depression have been shown to
influence the impact score in COPD because they
encompass the psychological and social dimension
of  the disease. It’s been suggested that variables
dependent on the psychological spheres exert a
decisive influence on the way in which patients live
with their disease and hence the HRQL26.
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Figure 1 (a-d):  Scatter plots showing the relationship of FEV1 and SGRQ component and total
scores
Figure 2: A matrix plots of SGRQ total score and Post bronchodilator FEV1 & FVC.
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 Lastly, the multiple regression analysis performed
using the SGRQ total score showed that adjusting
for age, sex, FEV1 and smoking, the model which
includes self reported breathlessness and weight loss
account for 35% of the variance in the SGRQ total
score. Weight loss has been reported as an indicator
of outcomes in numerous studies on COPD29, 30. In
our study, it accounted in the unadjusted model for
13% of the variance in the impact subscale and 11%
of  the total scores (data not shown). The aetiology
of weight loss in COPD is possibly multi-factorial
and factors implicated include increase workload of
laboured breathing, under-nutrition due to
breathlessness. The resultant effect is a reduction in
muscle strength, endurance and participation in social
activities and under-nourishment making COPD
patients prone to recurrent infection, increase
hospitalization and increased mortality from the
disease31.
This study has some limitations. It was a hospital-
based survey and as such, the participants included
in the study may be skewed towards the very sick
patients. Patients often do not access health care in
low resource settings until their clinical condition
becomes very dire because of the cost of care.  This
potentially limits the ability to generalise the results
of  this study to all COPD patients.
Conclusion
This study showed some important implications for
the care of  COPD in low-income settings.
Spirometry remains a core investigative modality in
the management of COPD however it should be
complemented with measures of quality of life. In
addition the presence of reported breathlessness
indicates poor health status and local clinicians may
use this variable as the primary indicator of  a patient’s
self-perceived quality of life. A simple measure of
breathlessness on a linear scale post exercise may also
provide significant guide into the clinical state of a
patient with COPD.
This study also showed that SGRQ quality scores
are weakly correlated with spirometry and it’s core
predictors are self-reported weight loss and
breathlessness.
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